Unknown

Dataset Information

0

Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity.


ABSTRACT: The field of T cell-based and chimeric antigen receptor (CAR)-engineered T (CAR-T) cell-based antitumor immunotherapy has seen substantial developments in the past decade; however, considerable issues, such as graft-versus-host disease (GvHD) and tumor-associated immunosuppression, have proven to be substantial roadblocks to widespread adoption and implementation. Recent developments in innate immune cell-based CAR therapy have opened several doors for the expansion of this therapy, especially as it relates to allogeneic cell sources and solid tumor infiltration. This study establishes in vitro killing assays to examine the TAM-targeting efficacy of MAIT, iNKT, and γδT cells. This study also assesses the antitumor ability of CAR-engineered innate T cells, evaluating their potential adoption for clinical therapies. The in vitro trials presented in this study demonstrate the considerable TAM-killing abilities of all three innate T cell types, and confirm the enhanced antitumor abilities of CAR-engineered innate T cells. The tumor- and TAM-targeting capacity of these innate T cells suggest their potential for antitumor therapy that supplements cytotoxicity with remediation of tumor microenvironment (TME)-immunosuppression.

SUBMITTER: Li YR 

PROVIDER: S-EPMC9179365 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity.

Li Yan-Ruide YR   Brown James J   Yu Yanqi Y   Lee Derek D   Zhou Kuangyi K   Dunn Zachary Spencer ZS   Hon Ryan R   Wilson Matthew M   Wilson Matthew M   Kramer Adam A   Zhu Yichen Y   Fang Ying Y   Yang Lili L  

Cancers 20220601 11


The field of T cell-based and chimeric antigen receptor (CAR)-engineered T (CAR-T) cell-based antitumor immunotherapy has seen substantial developments in the past decade; however, considerable issues, such as graft-versus-host disease (GvHD) and tumor-associated immunosuppression, have proven to be substantial roadblocks to widespread adoption and implementation. Recent developments in innate immune cell-based CAR therapy have opened several doors for the expansion of this therapy, especially a  ...[more]

Similar Datasets

| S-EPMC10146892 | biostudies-literature
| S-EPMC7832040 | biostudies-literature
| S-EPMC8022998 | biostudies-literature
| S-EPMC7873057 | biostudies-literature
| S-EPMC6299430 | biostudies-literature
| S-EPMC7674960 | biostudies-literature
| S-EPMC8801935 | biostudies-literature
| S-EPMC8361643 | biostudies-literature
| S-EPMC5851686 | biostudies-literature
| S-EPMC10858952 | biostudies-literature